Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook

被引：2

作者：

Zhou, Wenhao ^{[1
]}

Lu, Xiaojun ^{[1
]}

Tian, Feng ^{[2
]}

Luo, Qianming ^{[3
]}

Zhou, Weihang ^{[3
]}

Yang, Siyuan ^{[3
]}

Li, Wenxuan ^{[4
]}

Yang, Yongjun ^{[4
]}

Shi, Minfeng ^{[5
]}

Zhou, Tie ^{[1
]}

机构：

[1] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Dept Urol, Shanghai 200434, Peoples R China

[2] Shanghai Eighth Peoples Hosp, Dept Urol, Shanghai 200235, Peoples R China

[3] Tongji Univ, Sch Med, Shanghai 200092, Peoples R China

[4] Naval Med Univ, Coll Clin Med, Shanghai 200433, Peoples R China

[5] Naval Med Univ, Changhai Hosp, Reprod Ctr, Shanghai 200433, Peoples R China

来源：

VACCINES | 2024年 / 12卷 / 12期

关键词：

prostate cancer; cancer vaccines; immunotherapy; combination therapies; PERSONALIZED PEPTIDE VACCINATION; ANDROGEN DEPRIVATION THERAPY; PHASE I/II TRIAL; SIPULEUCEL-T; CELLULAR IMMUNOTHERAPY; IMMUNOLOGICAL EFFICACY; CLINICAL-TRIAL; DNA VACCINES; II TRIAL; ANTIGEN;

D O I：

10.3390/vaccines12121384

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Prostate cancer is a prevalent cancer in elderly men, and immunotherapy has emerged as a promising treatment approach in recent years. The aim of immunotherapy is to stimulate the body's immune system to target and destroy cancer cells. Cancer vaccines that are highly specific, safe, and capable of creating long-lasting immune responses are a key focus in cancer immunotherapy research. Despite progress in clinical trials showing positive results, the practical use of cancer vaccines still encounters various obstacles. The complexity of the immune microenvironment and variations in the immune systems of individual patients have hindered the progress of research on prostate cancer vaccines. This review examines the history and mechanisms of cancer vaccines, summarizes recent clinical research findings, and explores future directions in the development of prostate cancer vaccines.

引用

页数：15

共 80 条

[1] Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial [J].

Antonarakis, Emmanuel S. ;

Kibel, Adam S. ;

Yu, Evan Y. ;

Karsh, Lawrence I. ;

Elfiky, Aymen ;

Shore, Neal D. ;

Vogelzang, Nicholas J. ;

Corman, John M. ;

Millard, Frederick E. ;

Maher, Johnathan C. ;

Chang, Nancy N. ;

DeVries, Todd ;

Sheikh, Nadeem A. ;

Drake, Charles G. .

CLINICAL CANCER RESEARCH, 2017, 23 (10) :2451-2459

[2] Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite" [J].

Arina, Ainhoa ;

Gutiontov, Stanley I. ;

Weichselbaum, Ralph R. .

CLINICAL CANCER RESEARCH, 2020, 26 (12) :2777-2782

[3] Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer [J].

Beer, Tomasz M. ;

Bernstein, Guy T. ;

Corman, John M. ;

Glode, L. Michael ;

Hall, Simon J. ;

Poll, Wayne L. ;

Schellhammer, Paul F. ;

Jones, Lori A. ;

Xu, Yi ;

Kylstra, Jelle W. ;

Frohlich, Mark W. .

CLINICAL CANCER RESEARCH, 2011, 17 (13) :4558-4567

[4] Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) [J].

Bilusic, Marijo ;

McMahon, Sheri ;

Madan, Ravi A. ;

Karzai, Fatima ;

Tsai, Yo-Ting ;

Donahue, Renee N. ;

Palena, Claudia ;

Jochems, Caroline ;

Marte, Jennifer L. ;

Floudas, Charalampos ;

Strauss, Julius ;

Redman, Jason ;

Sater, Houssein Abdul ;

Rabizadeh, Shahrooz ;

Soon-Shiong, Patrick ;

Schlom, Jeffrey ;

Gulley, James L. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)

[5] Adenovirus Vectors: Excellent Tools for Vaccine Development [J].

Chang, Jun .

IMMUNE NETWORK, 2021, 21 (01) :1-11

[6] Impact of extracellular vesicles on innate immunity [J].

Chen, Zhizhao ;

Larregina, Adriana T. ;

Morelli, Adrian E. .

CURRENT OPINION IN ORGAN TRANSPLANTATION, 2019, 24 (06) :670-678

[7] DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time [J].

Chudley, Lindsey ;

McCann, Katy ;

Mander, Ann ;

Tjelle, Torunn ;

Campos-Perez, Juan ;

Godeseth, Rosemary ;

Creak, Antonia ;

Dobbyn, James ;

Johnson, Bernadette ;

Bass, Paul ;

Heath, Catherine ;

Kerr, Paul ;

Mathiesen, Iacob ;

Dearnaley, David ;

Stevenson, Freda ;

Ottensmeier, Christian .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (11) :2161-2170

[8] Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks [J].

Comiskey, Michael C. ;

Dallos, Matthew C. ;

Drake, Charles G. .

CURRENT ONCOLOGY REPORTS, 2018, 20 (09)

[9] Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice [J].

da Silva, Jamile Ramos ;

Rodrigues, Karine Bitencourt ;

Pelegrin, Guilherme Formoso ;

Sales, Natiely Silva ;

Muramatsu, Hiromi ;

Silva, Mariangela de Oliveira ;

Porchia, Bruna F. M. M. ;

Moreno, Ana Carolina Ramos ;

Aps, Luana Raposo M. M. ;

Venceslau-Carvalho, Alexia Adrianne ;

Tombacz, Istvan ;

Fotoran, Wesley Luzetti ;

Kariko, Katalin ;

Lin, Paulo J. C. ;

Tam, Ying K. ;

Diniz, Mariana de Oliveira ;

Pardi, Norbert ;

Ferreira, Luis Carlos de Souza .

SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (686)

[10] Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T [J].

Dorff, Tanya ;

Hirasawa, Yosuke ;

Acoba, Jared ;

Pagano, Ian ;

Tamura, David ;

Pal, Sumanta ;

Zhang, Minlu ;

Waitz, Rebecca ;

Dhal, Abhilash ;

Haynes, Winston ;

Shon, John ;

Scholz, Mark ;

Furuya, Hideki ;

Chan, Owen T. M. ;

Huang, Jeffrey ;

Rosser, Charles .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)

← 1 2 3 4 5 6 7 8 →